Glycopyrronium Ethypharm (Glycopyrronium Bromide)

Glycopyrronium Ethypharm is indicated for use in the peri‑operative period to manage excessive secretions.

• Preoperative reduction of salivary secretions to facilitate airway management.
• Decrease of respiratory tract secretions to improve ventilation during anesthesia.
• Control of bronchial secretions in patients undergoing thoracic surgery.
• Adjunctive use to reduce secretions in patients receiving anticholinergic therapy for other indications.
• Facilitation of endotracheal intubation by minimizing oral and pharyngeal moisture.

The safety profile of glycopyrronium bromide includes both frequent mild effects and rare serious reactions.

Common

• Dry mouth
• Throat irritation
• Transient increase in heart rate
• Mild facial flushing
• Nausea

Serious

• Severe hypotension
• Cardiac arrhythmias
• Anaphylactic reaction
• Acute urinary retention
• Bronchospasm

When prescribing Glycopyrronium Ethypharm, clinicians should consider several precautionary measures to ensure patient safety.

• Assess for known hypersensitivity to glycopyrronium or other anticholinergics.
• Use cautiously in patients with glaucoma, especially narrow‑angle type.
• Monitor cardiovascular status in individuals with pre‑existing heart disease.
• Avoid in patients with severe obstructive airway disease without specialist advice.
• Adjust dose or observe closely in the elderly due to increased sensitivity.
• Consider renal or hepatic impairment as it may affect drug clearance.

Glycopyrronium bromide may interact with other medications; awareness of these interactions helps prevent adverse effects.

Avoid

• Concurrent use with other anticholinergic agents (e.g., atropine, scopolamine) that may cause additive anticholinergic toxicity.
• Combination with drugs that prolong QT interval, increasing risk of cardiac arrhythmias.

Use with caution

• Beta‑adrenergic agonists (e.g., albuterol) as they may enhance tachycardia.
• Anesthetic agents such as succinylcholine, which may potentiate muscle relaxation.
• Antihypertensive medications, requiring blood pressure monitoring.
• Drugs affecting renal excretion, potentially altering glycopyrronium levels.